Archives
-
Stattic A2224: Reliable STAT3 Assay Design
2026-09-29
A scenario-driven guide to using Stattic (SKU A2224) in cell viability, proliferation, cytotoxicity, and STAT3-mechanism studies. It connects product-specific handling data with practical controls, protocol optimization, and evidence from cancer biology research.
-
D-Luciferin for Bladder Cancer Bioluminescence
2026-09-28
D-Luciferin potassium salt enables longitudinal, non-invasive monitoring of luciferase-labeled bladder cancer models, including studies of antimony-associated progression. Its water solubility, defined composition, and compatibility with in vivo and in vitro workflows support cleaner dosing, reporter assays, and troubleshooting.
-
Metabolomics Maps Carbapenemase-Linked Resistance
2026-09-28
A 2025 LC-MS/MS study profiled the endo- and exometabolomes of 32 Klebsiella pneumoniae and Escherichia coli isolates to identify metabolic features associated with carbapenemase production. Its machine-learning models distinguished CPE from non-CPE isolates using 21 candidate biomarkers, suggesting a route toward faster resistance detection while providing clues to the biology of the resistant phenotype.
-
Dabigatran Etexilate: Evidence from the 2011 Review
2026-09-27
The 2011 clinical review describes dabigatran etexilate as an oral prodrug that delivers reversible, direct thrombin inhibition, addressing several practical constraints of vitamin K antagonists and injectable anticoagulants. It synthesizes pharmacology, pharmacokinetics, and clinical evidence across venous thromboembolism and nonvalvular atrial fibrillation, while emphasizing bleeding risk, gastrointestinal tolerability, and renal function as important considerations.
-
Human iPSC Intestinal Organoids for PK Studies
2026-09-26
Saito and colleagues describe a human pluripotent stem cell-derived intestinal organoid platform designed to provide expandable, cryopreservable epithelial material for pharmacokinetic research. After conversion to monolayers, the organoids produced differentiated intestinal epithelial cells with drug-metabolizing enzyme and transporter activity, offering a human-relevant complement to animal models and Caco-2 assays.
-
NSC 87877 Workflows for SHP2 Neuroinflammation
2026-09-25
Use NSC 87877 to test whether SHP2 phosphatase activity contributes to microglial signaling—not to assume that SHP2 blockade will always reduce inflammation. This practical workflow connects dose selection and pathway readouts to stroke research while accounting for the compound’s SHP1 activity and the reference study’s context-dependent NLRP3 result.
-
L-Glutathione Reduced: Reading Redox in Cancer Metabolism
2026-09-25
L-Glutathione Reduced is more than an antioxidant reagent: it can help researchers distinguish redox changes from metabolic target engagement. This article connects glutathione assay design with GOT1-dependent cancer metabolism and explains the practical limits of that comparison.
-
Bifendate (DDB): Reading Liver Lipid Phenotypes
2026-09-24
Bifendate (DDB) research can reveal more than whether liver lipid accumulation falls: it can help distinguish metabolic change from altered autophagic processing. This article uses a berberrubine NAFLD study as a practical framework while clearly separating its findings from evidence specific to DDB.
-
Multiple Myeloma Cell Lines: Mutational Landscape
2026-09-24
This study used whole-exome sequencing to map protein-altering mutations across a diverse panel of human multiple myeloma cell lines and related genomic features to drug responses. Its findings offer a resource for choosing molecularly informed models, while highlighting that mutation–response associations require functional validation before being treated as mechanisms of resistance.
-
Azathramycin A: Workflows for TB Ribosome Research
2026-09-23
Use Azathramycin A to connect macrolide ribosome binding with orthogonal assays of protein synthesis and bacterial response—not as a stand-alone proof of antibacterial efficacy. A susceptibility-first workflow, informed by a kitasamycin study in swine dysentery, helps researchers separate target engagement from organism-level activity and resistance.
-
Chlorambucil: From DNA Damage to Translation
2026-09-23
A translational framework for using Chlorambucil to connect DNA crosslinking, assay design, and clinically relevant interpretation beyond conventional single-endpoint product pages.
-
Mianserin HCl Assay Workflows and Use Cases
2026-09-22
Mianserin HCl combines 5-HT2 receptor antagonism with a distinctive cyclodextrin-dependent cytotoxicity profile. This practical guide converts receptor, formulation, and antipathogenic evidence into executable assay workflows with controls designed to separate target biology from exposure effects.
-
Psora 4: Rethinking Selective Kv1.3 Blockade
2026-09-22
Psora 4 offers a powerful framework for studying how Kv1.3-dependent membrane potential control shapes T cell calcium signaling, effector-memory T cell function, and inflammatory disease biology. This thought-leadership perspective connects channel pharmacology, KCNE4-dependent channel architecture, experimental design, and translational strategy.
-
IGF2BP2 Links m6A Signaling to Ovarian Cancer Glycolysis
2026-09-21
This 2026 study combines single-cell and bulk transcriptomics with genetic, metabolic, flow-cytometric, and RIP-seq analyses to identify IGF2BP2 as a malignant epithelial-cell-associated m6A reader in ovarian cancer. The findings connect IGF2BP2 to cell-cycle progression, apoptosis resistance, and glycolytic maintenance, while pharmacological inhibition supports its potential as a therapeutic vulnerability.
-
Etoposide and LAMP1: DNA Damage to Senescence
2026-09-21
Etoposide (VP-16) is more than a DNA damage control: it can help researchers distinguish apoptotic responses from persistent stress phenotypes. This guide connects topoisomerase II inhibition with LAMP1-based senescence analysis and practical assay design.